RRML - FasL is expressed in human breast cancer endothelia. Who benefits?

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17

Advanced search

Top 10 downloaded articles
- February 2023 -
On the relationship between CT... 6
The Role of procollagen type 1... 6
Association of HLA class II al... 5
Making the most out of profici... 5
Management of a case of Castle... 4
The Role of Prostate-Specific ... 3
Ischemia modified albumin in e... 3
The potential of programmed de... 3
Atellica CH 930 chemistry anal... 3
Ferritin and procalcitonin in ... 3

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 20(1)/2012

FasL is expressed in human breast cancer endothelia. Who benefits?

Corina M. Cianga, Irina D. Florea, Petru Cianga


Background: Fas ligand (FasL) expression is one of the mechanisms responsible for the “immune privi-lege” of tissues such as testis and eye. Many solid tumors express FasL as an immune escape strategy, aiming to induce apoptosis in Fas-expressing leukocytes, and thus to prevent the accumulation of effector cells. Materials and Methods: We investigated by immunohistochemistry the FasL expression in human breast carcinomas vasculature (blood vessels versus lymphatics), endothelial activation status and markers associated with tumor aggressiveness. Results: We bring evidence of a heterogeneous FasL expression in the human breast carcinomas associated blood vessels, but not lymphatics. The endothelial FasL expression was significantly correlated with the tumor FasL expression, tumor size, the presence of rich vascular networks, and axillary lymph nodes metastases; however, it was not correlated with low tumor invading leukocytes density. Conclusion: Breast carcinomas are among tumors in which the tumor-host interaction is correlated with the clinical outcome, hence understanding the significance of endothelial FasL expression is of outmost importance.

Keywords: FasL,breast carcinoma,endothelium,immune privilege,tolerance

  PDF Download full text PDF
(651 KB)
How to cite
Cianga CM, Florea ID, Cianga P. FasL is expressed in human breast cancer endothelia. Who benefits?. Rev Romana Med Lab. 2012;20(1):45-56